EP1012238A4 - CELLS WITH PEPTIDES OR ANTIGENS WITH PEPTIDES - Google Patents

CELLS WITH PEPTIDES OR ANTIGENS WITH PEPTIDES

Info

Publication number
EP1012238A4
EP1012238A4 EP98906086A EP98906086A EP1012238A4 EP 1012238 A4 EP1012238 A4 EP 1012238A4 EP 98906086 A EP98906086 A EP 98906086A EP 98906086 A EP98906086 A EP 98906086A EP 1012238 A4 EP1012238 A4 EP 1012238A4
Authority
EP
European Patent Office
Prior art keywords
peptides
antigens
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98906086A
Other languages
German (de)
French (fr)
Other versions
EP1012238A1 (en
Inventor
Van Tsai
Scott Southwood
John Sidney
Alessandro Sette
Esteban Celis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1012238A1 publication Critical patent/EP1012238A1/en
Publication of EP1012238A4 publication Critical patent/EP1012238A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP98906086A 1997-01-31 1998-01-30 CELLS WITH PEPTIDES OR ANTIGENS WITH PEPTIDES Withdrawn EP1012238A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3669697P 1997-01-31 1997-01-31
US36696P 1997-01-31
PCT/US1998/001959 WO1998033888A1 (en) 1997-01-31 1998-01-30 Peptides and peptide-loaded antigen presenting cells for the activation of ctl

Publications (2)

Publication Number Publication Date
EP1012238A1 EP1012238A1 (en) 2000-06-28
EP1012238A4 true EP1012238A4 (en) 2003-03-05

Family

ID=21890106

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98906086A Withdrawn EP1012238A4 (en) 1997-01-31 1998-01-30 CELLS WITH PEPTIDES OR ANTIGENS WITH PEPTIDES

Country Status (5)

Country Link
EP (1) EP1012238A4 (en)
JP (1) JP2001509677A (en)
AU (1) AU6140998A (en)
CA (1) CA2278189A1 (en)
WO (1) WO1998033888A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IT1309584B1 (en) * 1999-02-26 2002-01-24 San Raffaele Centro Fond IMMUNOGENIC PEPTIDES DERIVED FROM MAGE-3 PRESENTED BY MHC OF CLASS II AND THEIR USE.
ATE512666T1 (en) * 1999-06-29 2011-07-15 Epimmune Inc HLA-BINDING PEPTIDES AND THEIR USES
EP1230268B1 (en) 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
EP1235848A4 (en) * 1999-12-10 2005-02-09 Epimmune Inc Stimulation of CULLARY IMMUNE RESPONSES for a CARCINOEMBRYONES ANTIGEN USING PEPTIDES AND NUCLEIC ACID COMPOSITIONS
JP2003516344A (en) * 1999-12-13 2003-05-13 エピミューン， インコーポレイテッド HLA class IA2 tumor-associated antigenic peptides and vaccine compositions
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
EP1303287A4 (en) * 2000-06-16 2006-02-08 Argonex Pharmaceuticals MHC OUREXPRIMES PEPTIDES ON PROSTATE CANCER CELLS AND METHODS OF USE
EP1312670A4 (en) * 2000-08-16 2005-11-30 Takara Bio Inc PROCESS FOR THE EXTENSIVE CULTURE OF ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES
CA2420225A1 (en) * 2000-09-01 2002-03-14 Pharmexa Inc. Hla-a2.1 binding peptides and their uses
AU2002257647A1 (en) * 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
AU2002305138A1 (en) 2001-04-09 2002-10-21 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
KR100888915B1 (en) 2001-08-15 2009-03-16 다카라 바이오 가부시키가이샤 Method of extended culture for antigen-specific cytotoxic t lymphocytes
JP4406566B2 (en) 2002-03-25 2010-01-27 タカラバイオ株式会社 Method for producing cytotoxic lymphocytes
PT1620456E (en) 2003-04-18 2014-04-15 Biotech Synergy Inc TUMOR-ASSOCIATED HLA-A2 ANTIGENIC PEPTIDES AND THEIR COMPOSITIONS
WO2005007694A1 (en) * 2003-07-16 2005-01-27 Green Peptide Co., Ltd. HER2/neu PEPTIDE AND THERAPEUTIC USE TEHREOF
KR101331746B1 (en) 2003-08-22 2013-11-20 다카라 바이오 가부시키가이샤 Process for producing cytotoxic lymphocytes
EP1715343B1 (en) * 2005-04-20 2009-12-09 F. Hoffmann-La Roche Ag Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
EP1916302A4 (en) 2005-08-17 2009-10-21 Takara Bio Inc PROCESS FOR THE PRODUCTION OF LYMPHOCYTES
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CN102625832A (en) 2009-08-24 2012-08-01 贝勒医学院 Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses
AU2012258603A1 (en) 2011-05-26 2014-01-16 Geneius Biotechnology, Inc. Modulated immunodominance therapy
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
KR101749195B1 (en) 2011-12-12 2017-06-20 셀 메디카 리미티드 Process of expanding t cells
ES2748652T3 (en) 2012-02-09 2020-03-17 Baylor College Medicine Pep mixes to generate multiviral CTLs with broad specificity
EP3350600A4 (en) 2015-09-18 2019-04-17 Baylor College of Medicine IDENTIFICATION OF IMMUNOGENIC ANTIGEN FROM PATHOGEN AND CORRELATION WITH CLINICAL EFFICIENCY
CN105175527B (en) * 2015-10-09 2021-06-04 深圳市康尔诺生物技术有限公司 Breast cancer specific heat shock protein complex and application thereof
JP7019578B2 (en) * 2015-12-30 2022-02-15 セルジーン コーポレイション Method of producing T lymphocytes and T lymphocytes produced thereby
US12247053B2 (en) 2018-10-26 2025-03-11 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAKKER A B H ET AL: "GENERATION OF ANTIMELANOMA CYTOTOXIC T LYMPHOCYTES FROM HEALTHY DONORS AFTER PRESENTATION OF MELANOMA-ASSOCIATED ANTIGEN-DERIVED EPITOPES BY DENDRITIC CELLS IN VITRO", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 55, no. 22, 15 November 1995 (1995-11-15), pages 5330 - 5334, XP002032191, ISSN: 0008-5472 *
BOON T ET AL: "TUMOR ANTIGENS RECOGNIZED BY T LYMPHOCYTES", ANNUAL REVIEW OF IMMUNOLOGY, ANNUAL REVIEWS INC, US, VOL. 12, PAGE(S) 337-365, ISSN: 0732-0582, XP000882320 *
CHEN W-F ET AL: "IL-10 A NOVEL CYTOTOXIC T CELL DIFFERENTIATION FACTOR", JOURNAL OF IMMUNOLOGY, vol. 147, no. 2, 1991, pages 528 - 534, XP002220425, ISSN: 0022-1767 *
KAWASHIMA I ET AL: "IDENTIFICATION OF GP100-DERIVED, MELANOMA-SPECIFIC CYTOTOXIC PRIMARY IN VITRO IMMUNIZATION WITH PEPTIDE-PULSED DENDRITIC CELLS. T-LYMPHOCYTE EPITOPES RESTRICTED BY HLA-A3 SUPERTYPE MOLECULES BY", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 78, no. 4, 1998, pages 518 - 524, XP000917221, ISSN: 0020-7136 *
ROMANI N ET AL: "PROLIFERATING DENDRITIC CELL PROGENITORS IN HUMAN BLOOD", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 180, no. 1, 1 July 1994 (1994-07-01), pages 83 - 93, XP000610046, ISSN: 0022-1007 *
See also references of WO9833888A1 *
TSAI V ET AL: "IDENTIFICATION OF SUBDOMINANT CTL EPITOPES OF THE GP 100 MELANOMA-ASSOCIATED TUMOR ANTIGEN BY PRIMARY IN VITRO IMMUNIZATION WITH PEPTIDE-PULSED DENDRITIC CELLS", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 158, no. 4, 1997, pages 1796 - 1802, XP000919288, ISSN: 0022-1767 *
YANG GUCHEN ET AL: "In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation.", JOURNAL OF IMMUNOLOGY, vol. 155, no. 8, 1995, pages 3897 - 3903, XP002220424, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO1998033888A1 (en) 1998-08-06
EP1012238A1 (en) 2000-06-28
AU6140998A (en) 1998-08-25
JP2001509677A (en) 2001-07-24
CA2278189A1 (en) 1998-08-06

Similar Documents

Publication Publication Date Title
EP1012238A4 (en) CELLS WITH PEPTIDES OR ANTIGENS WITH PEPTIDES
DE69824784D1 (en) fuel cell
DE69606993D1 (en) RECHARGEABLE CAR INJECTOR
DE69634735D1 (en) FUEL CELL
DE69619112D1 (en) Improved positive charge pump
NO982519L (en) Shaped charge
NO962711L (en) Shaped charge
IS5375A (en) KAY-Innovative Immune Protein
DE59807059D1 (en) FUEL INJECTION
DE69828539D1 (en) shaped charge
PT1024358E (en) DENSOMETER
ATE245183T1 (en) ALTERNATIVE FUEL
DK1005652T3 (en) Binding assay using antigens embedded in thermoplastics
NO963008D0 (en) Shaped charge
NO963009D0 (en) Shaped charge
DE59806710D1 (en) FUEL INJECTION
DE59801536D1 (en) FUEL SYSTEM
FR2771493B1 (en) PROPULSIVE CHARGE SOCKET
DE69830355D1 (en) Fuel cap
DE69819580D1 (en) Fuel cap
DE69801419D1 (en) FUEL POST
DE69822240D1 (en) Fuel cap
DE69606884D1 (en) STRATIFIED CHARGING ENGINE
DE69801093D1 (en) Five-layer battery separator
DE69830356D1 (en) Fuel cap

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990812

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EPIMMUNE INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 9/08 B

Ipc: 7C 12N 5/08 B

Ipc: 7C 12N 5/06 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030121

18D Application deemed to be withdrawn

Effective date: 20020801